Description

Faslodex is a medication that contains the active substance fulvestrant. It is used to treat certain types of breast cancer. Here are some key details about Faslodex:

Mechanism of Action: Fulvestrant, the active ingredient in Faslodex, is a selective estrogen receptor degrader (SERD). It works by binding to estrogen receptors in breast cancer cells, leading to their degradation and inhibition of estrogen signaling. This helps to slow down the growth and spread of breast cancer cells.

Dosage: Faslodex is available as a liquid formulation with a concentration of 250 mg/ml. The recommended dose of Faslodex for metastatic breast cancer is 500 mg (two injections of 250 mg) administered intramuscularly (into the muscle) on days 1, 15, and 29, and then once monthly thereafter.

Administration: Faslodex should be administered by a healthcare professional as an intramuscular injection. The injection site can be the buttocks or the outer part of the thigh. The liquid formulation should be inspected visually for particulate matter and discoloration before administration, and it should be discarded if it is discolored or contains particles.

Adverse Effects: Common side effects of Faslodex may include injection site reactions (such as pain, swelling, or redness), nausea, vomiting, headache, and hot flashes. More serious side effects may include liver problems, lung problems, and allergic reactions. It’s essential to report any unusual or severe side effects to your healthcare provider.

Precautions: Faslodex should not be used in women who are pregnant or breastfeeding. It should be used with caution in patients with liver or lung problems. Faslodex may interact with certain medications, so it’s important to inform your healthcare provider about all medications, supplements, and medical conditions before starting Faslodex.